UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

The New England journal of medicine, 2014-09, Vol.371 (11), p.1028-1038

2014

Volltextzugriff (PDF)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer

Nature communications, 2020-06, Vol.11 (1), p.2689-14, Article 2689

2020

Volltextzugriff (PDF)

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

Cancer research (Chicago, Ill.), 2012-07, Vol.72 (14), p.3457-3462

2012

Volltextzugriff (PDF)

Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations

Prostate cancer and prostatic diseases, 2020-09, Vol.23 (3), p.381-397

2020

Volltextzugriff (PDF)

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

Proceedings of the National Academy of Sciences - PNAS, 2018-06, Vol.115 (26), p.6810-6815

2018

Volltextzugriff (PDF)

AR Splicing Variants and Resistance to AR Targeting Agents

Cancers, 2021-05, Vol.13 (11), p.2563

2021

Volltextzugriff (PDF)

Androgen receptor variant-driven prostate cancer II: advances in clinical investigation

Prostate cancer and prostatic diseases, 2020-09, Vol.23 (3), p.367-380

2020

Volltextzugriff (PDF)

Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy–naïve salivary duct carcinomas

Human pathology, 2019-02, Vol.84, p.173-182

2019

Volltextzugriff (PDF)

Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors

Journal of molecular endocrinology, 2010-03, Vol.44 (3), p.143-154

2010

Volltextzugriff (PDF)

Growth Activation Alone Is Not Sufficient to Cause Metastatic Thyroid Cancer in a Mouse Model of Follicular Thyroid Carcinoma

Endocrinology (Philadelphia), 2010-04, Vol.151 (4), p.1929-1939

2010

Volltextzugriff (PDF)

Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer

Carcinogenesis (New York), 2007-12, Vol.28 (12), p.2451-2458

2007

Volltextzugriff (PDF)

Regulation of β-Catenin by a Novel Nongenomic Action of Thyroid Hormone β Receptor

Molecular and Cellular Biology, 2008-07, Vol.28 (14), p.4598-4608

2008

Volltextzugriff (PDF)

Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1)

Proceedings of the National Academy of Sciences - PNAS, 2011-10, Vol.108 (42), p.17462-17467

2011

Volltextzugriff (PDF)

Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer

Carcinogenesis (New York), 2010-07, Vol.31 (7), p.1284-1291

2010

Volltextzugriff (PDF)

Decoding the androgen receptor splice variants

Translational andrology and urology, 2013-09, Vol.2 (3), p.178-186

2013

Volltextzugriff (PDF)

RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients

Materials today bio, 2022-12, Vol.17, p.100474-100474, Article 100474

2022

Volltextzugriff (PDF)

Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary Tumors

Endocrinology (Philadelphia), 2008-07, Vol.149 (7), p.3339-3345

2008

Volltextzugriff (PDF)

Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis

Steroids, 2011-08, Vol.76 (9), p.885-891

2011

Volltextzugriff (PDF)

Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors

Steroids, 2009-07, Vol.74 (7), p.628-634

2009

Volltextzugriff (PDF)

Nuclear Receptor Corepressor Is a Novel Regulator of Phosphatidylinositol 3-Kinase Signaling

Molecular and Cellular Biology, 2007-09, Vol.27 (17), p.6116-6126

2007

Volltextzugriff (PDF)

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2149-2156

2017

Volltextzugriff (PDF)

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

European urology, 2018-08, Vol.74 (2), p.218-225

2018

Volltextzugriff (PDF)

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

The lancet oncology, 2018-01, Vol.19 (1), p.76-86

2018

Volltextzugriff (PDF)

Abstract 909: Development and characterization of androgen receptor knockout prostate cancer cell lines by CRISPR-Cas9

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.909-909

2018

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

AR Splicing Variants and Resistance to AR Targeting Agents

Androgen receptor variant-driven prostate cancer II: advances in clinical investigation

Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy–naïve salivary duct carcinomas

Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors

Growth Activation Alone Is Not Sufficient to Cause Metastatic Thyroid Cancer in a Mouse Model of Follicular Thyroid Carcinoma

Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer

Regulation of β-Catenin by a Novel Nongenomic Action of Thyroid Hormone β Receptor

Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1)

Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer

Decoding the androgen receptor splice variants

RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients

Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary Tumors

Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis

Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors

Nuclear Receptor Corepressor Is a Novel Regulator of Phosphatidylinositol 3-Kinase Signaling

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

Abstract 909: Development and characterization of androgen receptor knockout prostate cancer cell lines by CRISPR-Cas9

Suchergebnisse filtern